[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495342":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":25,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":25,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":25,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Kentucky","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intranasal Opioid Agonist","EXPERIMENTAL","Participants will receive non-therapeutic, experimental doses of an opioid agonist or placebo. Active opioid agonist\u002Fplacebo will be administered once per session and will be administered intransally (snorting).",[13,14],"Drug: Inhaled vaporized cannabis","Drug: Intransal opioid",{"label":16,"type":10,"description":17,"interventionNames":18},"Vaporized cannabis","Participants will receive non-therapeutic, experimental doses of active or placebo vaporized cannabis. Active cannabis\u002Fplacebo will be administered once per session and will be administered via a vaporizer.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Inhaled vaporized cannabis","Double-blind cannabis and placebo doses, administered through vaporizer",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Intransal opioid","Double-blind opioid and placebo doses, administered intranasal route",[9,16],[31],{"name":32,"affiliation":5,"role":33},"Shanna Babalonis, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Paul Nuzzo, MA","CONTACT","859-323-0002","pnuzz2@email.uky.edu",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Center on Drug and Alcohol Research","RECRUITING","Lexington","Kentucky","40508","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-84.47772,37.98869,{"lat":53,"lon":52},[56],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"type":58,"investigatorFullName":32,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Principal Investigator",[61],{"name":62,"class":63},"National Institute on Drug Abuse (NIDA)","NIH","100495342","phase-1-cannabis-and-opioid-use-disorder-100495342",false,"NCT05729932","Cannabis and Opioid Use Disorder","Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Abuse Potential and Safety","Inclusion Criteria:\n\n* Current opioid use disorder\n\nExclusion Criteria:\n\n* Current medical conditions that require medical management",true,"ALL","18 Years","55 Years",{"count":76,"type":77},15,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.",[83],"Opioid Use Disorder","2026-06-16",{"date":86,"type":87},"2026-06-18","ACTUAL",{"date":89,"type":87},"2024-09-10",{"date":91,"type":77},"2027-06-30",{"name":32,"class":6},1]